94689-7

CD20 cells/100 CD19 cells in Blood

Active

Part Descriptions

LP17751-6   Cells.CD20
B-lymphocyte antigen CD20 or CD20 is an activated-glycosylated phosphoprotein on the surface of all B-cells starting at the pro-B phase (CD45R+, CD117+) and increases in concentration until maturity. In humans CD20 is encoded by the MS4A1 gene. This gene encodes a member of the membrane-spanning 4A gene family. Members of this nascent protein family are characterized by common structural features and similar intron/exon splice boundaries and display unique expression patterns among hematopoietic cells and nonlymphoid tissues. This gene encodes a B-lymphocyte surface molecule that plays a role in the development and differentiation of B-cells into plasma cells. CD20 is the target of the monoclonal antibodies (mAb) rituximab, Ibritumomab tiuxetan, and tositumomab, that are active agents in the treatment of all B cell lymphomas and leukemias. The anti-CD20 mAB Ofatumumab (Genmab) was approved by FDA in Oct 2009 for Chronic lymphocytic leukemia. Copyright Text is available under the Creative Commons Attribution/Share-Alike License. See http://creativecommons.org/licenses/by-sa/3.0/ for details. Source: Wikipedia, CD20

LP266978-8   100 Cells.CD19
The CD19+ B cells are 95 kilo Dalton transmembrane glycoproteins and are comprised of a single transmembrane domain, a cytoplasmic C-terminus, and an extracellular N-terminus. It is a biomarker for normal and neoplastic B cells and for dendritic cells. CD19+ B cells regulate signaling thresholds by modifying B cell receptor dependent and independent signaling, functioning as a dominant piece of a multimolecular complex that resides on the mature B cell surface. The concentration of CD19 on the surface of B cells is tightly controlled throughout the cell's development, making it a very valuable biomarker for B cells. Mature B cells have three times the number of CD19 antigens than immature B cells, and when B cells differentiate into plasma cells, the expression of CD19 is lost. Patients who lack sufficient CD19 antigens have a lower response to transmembrane signals and weak T cell dependent antibody responses. CD19 is highly conserved and expressed in most B cell malignancies including acute lymphocytic leukemia, B cell lymphoma, and B cell leukemia. Efforts are in play to utilize CD19 antibodies for the treatment of lymphoma, leukemia, and autoimmune disorders. PMID: 23210908 Source: Regenstrief LOINC

Fully-Specified Name

Component

Cells.CD20/100 cells.CD19

Property

NFr

Time

Pt

System

Bld

Scale

Qn

Method

Additional Names

Short Name

CD20 Cells/100 CD19 cells NFr Bld

Display Name

CD20 cells/100 CD19 cells (Bld)

Consumer Name Alpha Get Info

CD20 cells per 100 CD19 Cells, Blood

Basic Attributes

Class

CELLMARK

Type

Laboratory

First Released

Version 2.68

Last Updated

Version 2.73

Order vs. Observation

Observation

Common Test Rank Get Info

5306

Language Variants Get Info

Related Names

• 100 CD19 cells
• B Cells
• B cells expressing CD19 as a percent of total lymphocytes
• B1
• B-1
• B4
• B-4
• Blood
• Bp35
• CD19 Cells
• CD20 Cells
• Cell
• CELL MARKERS
• Cellularity
• HD-37
• Hematology
• Heme
• Leu12
• Leu-12
• Leu16
• Leu-16
• Number fraction
• Percent
• Point in time
• QNT
• Quan
• Quant
• Quantitative
• Random
• WB
• Whole blood

Example Units

LOINC Terminology Service (API) using HL7^® FHIR^® Get Info

Requests to this service require a free LOINC username and password. Below is a sample of the possible capabilities. See the LOINC Terminology Service documentation for more information.

CodeSystem lookup

https://fhir.loinc.org/CodeSystem/$lookup?system=http://loinc.org&code=94689-7

LOINC Copyright

Copyright © 2024 Regenstrief Institute, Inc. All Rights Reserved. To the extent included herein, the LOINC table and LOINC codes are copyright © 1995-2024, Regenstrief Institute, Inc. and the Logical Observation Identifiers Names and Codes (LOINC) Committee. See https://loinc.org/license for the full LOINC copyright and license.